Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015, Article ID 232915, 4 pages
http://dx.doi.org/10.1155/2015/232915
Case Report

Isolated Central Nervous System Relapse in Chronic Myeloid Leukemia

1Internal Medicine Department, Guillermo Almenara Irigoyen National Hospital, Grau Avenue 800, Lima, Peru
2National Institute of Neurologic Sciences, Ancash Street 1271, Barrios Altos, Lima, Peru

Received 23 October 2014; Revised 8 March 2015; Accepted 9 March 2015

Academic Editor: Lothar Bergmann

Copyright © 2015 Juliana Gomez and Victor Duenas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Rowley, “A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining,” Nature, vol. 243, no. 5405, pp. 290–293, 1973. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Eric and M. Hsi, Hematopathology—A Volume in Foundations in Diagnostic Pathology Series, Philadelphia Churchill Livingstone, 1st edition, 2006.
  3. E. Jabbour and H. Kantarjian, “Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management,” American Journal of Hematology, vol. 87, no. 11, pp. 1037–1045, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haemotopietic and Lymphoid Tissues, IARC Press, Lyon, France, 4th edition, 2008.
  5. S. Rajappa, S. G. Uppin, D. Raghunadharao, I. S. Rao, and A. Surath, “Isolated central nervous system blast crisis in chronic myeloid leukemia,” Hematological Oncology, vol. 22, no. 4, pp. 179–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Pfeifer, B. Wassmann, W.-K. Hofmann et al., “Risk and prognosis of central nervous system leukemia in patients with philadelphia chromosome-positive acute leukemias treated with imatinib mesylate,” Clinical Cancer Research, vol. 9, no. 13, pp. 4674–4681, 2003. View at Google Scholar · View at Scopus
  7. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Altintas, T. T. Cil, I. Kilinc, M. A. Kaplan, and O. Ayyildiz, “Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report,” Journal of Neuro-Oncology, vol. 84, no. 1, pp. 103–105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Park, P. H. Park, Y. H. Seo et al., “A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib,” Annals of Laboratory Medicine, vol. 34, no. 3, pp. 247–251, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Lindhorst, R. D. Lopez, and R. D. Sanders, “An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse,” Journal of the National Comprehensive Cancer Network, vol. 11, no. 7, pp. 745–750, 2013. View at Google Scholar · View at Scopus
  11. Y. Isobe, K. Sugimoto, A. Masuda, Y. Hamano, and K. Oshimi, “Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate,” Internal Medicine Journal, vol. 39, no. 6, pp. 408–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Bornhauser, A. Jenke, J. Freiberg-Richter et al., “CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid,” Annals of Hematology, vol. 83, no. 6, pp. 401–402, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Rytting and W. G. Wierda, “Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy,” Leukemia & Lymphoma, vol. 45, no. 8, pp. 1623–1626, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. J. Aichberger, S. Herndlhofer, H. Agis et al., “Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy,” European Journal of Clinical Investigation, vol. 37, no. 10, pp. 808–813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Nishimoto, H. Nakamae, K.-R. Koh et al., “Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia,” Acta Haematologica, vol. 130, no. 2, pp. 111–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. A. Johnson, R. Fetni, and S. N. Caplan, “Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate,” Leukemia and Lymphoma, vol. 46, no. 4, pp. 629–630, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Matsuda, Y. Morita, T. Shimada et al., “Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate,” International Journal of Hematology, vol. 81, no. 4, pp. 307–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. Kim, C. W. Jung, K. Kim et al., “Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 4028–4029, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Barlow, M. Robertson, A. Doig, W. Stewart, and M. W. Drummond, “Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission,” British Journal of Haematology, vol. 142, no. 3, p. 327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. W. Lee, M. K. Song, Y. M. Seol et al., “Isolated central nervous system blast crisis in chronic myeloid leukemia,” The Korean Journal of Medicine, vol. 77, supplement 2, pp. S441–S444, 2009. View at Google Scholar
  21. A. Thomas, C. K. Stein, T. C. Gentile, and C. M. Shah, “Isolated CNS relapse of CML after bone marrow transplantation,” Leukemia Research, vol. 34, no. 4, pp. e113–e114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Fuchs, M. Reinhöfer, A. Ragoschke-Schumm et al., “Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation,” BMC Blood Disorders, vol. 12, article 9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Deininger, S. G. O'Brien, F. Guilhot et al., “International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib,” Blood, vol. 114, no. 22, p. 462, 2009, Abstract 1126. View at Google Scholar
  26. J. F. Leis, D. E. Stepan, P. T. Curtin et al., “Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571),” Leukemia & Lymphoma, vol. 45, no. 4, pp. 695–698, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Dai, P. Marbach, M. Lemaire, M. Hayes, and W. F. Elmquist, “Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 3, pp. 1085–1092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Porkka, P. Koskenvesa, T. Lundán et al., “Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia,” Blood, vol. 112, no. 4, pp. 1005–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. O'Hare, D. K. Walters, E. P. Stoffregen et al., “In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants,” Cancer Research, vol. 65, no. 11, pp. 4500–4505, 2005. View at Publisher · View at Google Scholar · View at Scopus